Literature DB >> 10484247

Cost of Alzheimer's disease and related dementia in managed-medicare.

E M Gutterman1, J S Markowitz, B Lewis, H Fillit.   

Abstract

BACKGROUND: Managed care organizations (MCOs) will have increased responsibility for the care of large numbers of persons with dementia. There are, however, few studies that inform about decisions of healthcare utilization and expenditures for individuals with dementia in managed care.
OBJECTIVES: To examine in a large MCO whether people diagnosed with dementia have higher healthcare utilization and costs than enrollees without dementia.
DESIGN: A retrospective study of medical and prescription claims.
SETTING: An MCO covering more than 80,000 Medicare enrollees in four geographical locales between January 1, 1996, and March 31, 1998.
SUBJECTS: There were 677 paired cases with and without dementia. Controls were selected randomly and matched to cases on age, gender, and region. MEASUREMENTS: Summed total costs and number of claims accrued during the study period, as well as a breakdown of costs and claims with respect to place of service, were annualized and adjusted for age, gender, and comorbid conditions. Costs and claims were broken down by place of service.
RESULTS: Dementia prevalence was 0.83%. Mean total costs were 1.5 times higher for patients with dementia relative to controls ($13,487 vs $9,276, P < .001) when annualized and adjusted for level of comorbidity. Almost 75% of the higher costs among cases were linked to inpatient expenses.
CONCLUSIONS: Higher costs for individuals with dementia and disproportionate inpatient costs in this MCO parallel patterns among Medicare enrollees in fee-for-service. The high prevalence of dementia among the oldest old coupled with the high costs of dementia care create very significant clinical and financial incentives for managed care plans to improve the care of members suffering from dementia.

Entities:  

Mesh:

Year:  1999        PMID: 10484247     DOI: 10.1111/j.1532-5415.1999.tb05228.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  25 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

3.  Care coordination for cognitively impaired older adults and their caregivers.

Authors:  Mary D Naylor; Karen B Hirschman; Kathryn H Bowles; M Brian Bixby; JoAnne Konick-McMahan; Caroline Stephens
Journal:  Home Health Care Serv Q       Date:  2007

Review 4.  Case-control studies in pharmacoeconomic research: an overview.

Authors:  J Jaime Caro; Krista F Huybrechts
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 5.  Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence?

Authors:  Mark B Snowden; Lesley E Steinman; Lucinda L Bryant; Monique M Cherrier; Kurt J Greenlund; Katherine H Leith; Cari Levy; Rebecca G Logsdon; Catherine Copeland; Mia Vogel; Lynda A Anderson; David C Atkins; Janice F Bell; Annette L Fitzpatrick
Journal:  Int J Geriatr Psychiatry       Date:  2017-02-01       Impact factor: 3.485

Review 6.  Case management approaches to home support for people with dementia.

Authors:  Siobhan Reilly; Claudia Miranda-Castillo; Reem Malouf; Juanita Hoe; Sandeep Toot; David Challis; Martin Orrell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-05

7.  "Dementia-friendly hospitals: care not crisis": an educational program designed to improve the care of the hospitalized patient with dementia.

Authors:  James E Galvin; Barbara Kuntemeier; Noor Al-Hammadi; Jessica Germino; Maggie Murphy-White; Janis McGillick
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Oct-Dec       Impact factor: 2.703

Review 8.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  Dementia and out-of-pocket spending on health care services.

Authors:  Adeline Delavande; Michael D Hurd; Paco Martorell; Kenneth M Langa
Journal:  Alzheimers Dement       Date:  2012-11-13       Impact factor: 21.566

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.